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Abstract
This article provides an overview of trials relevant to the pathophysiology, pre-
vention, and treatment of heart failure, presented at the European Society of
Cardiologymeeting held in Barcelona in autumn2014. Trials reported here include
PARADIGM-HF (LCZ696 versus enalapril in heart failure), CONFIRM-HF
(treatment of iron deﬁciency in heart failure), and SIGNIFY (ivabradine in
patients with stable coronary artery disease). In addition, we discuss recent
developments in the treatment of atrial ﬁbrillation and the lack of beneﬁt with
the use of beta-blockers in these patients. Finally, the article describes recent
advances in the use of vagal stimulation in patients with heart failure. ©
2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on
behalf of the European Society of Cardiology.
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Paradigm-HF
Presented by John McMurray from the University of Glasgow, UK
Paradigm-HF1 was the most eagerly awaited of all the presentations at the
European Society of Cardiology (ESC) this year. The medical treatment of
chronic heart failure as a result of left ventricular systolic dysfunction has been
one of the great successes of modern medicine, and the approach of triple ther-
apy with beta-blocker, angiotensin converting enzyme inhibitor, and mineralo-
corticoid receptor antagonist has led to a halving of mortality from the
condition. However, with the exception of ivabradine for some patients, there
have been no great advances in standard medical treatment for many years.
LCZ696 is a combination of the angiotensin receptor antagonist (ARA),
valsartan, and the neprilysin inhibitor, sacubitril. Neprilysin is the enzyme
responsible for the breakdown of natriuretic peptides (as well as other vasoactive
peptides), and so its inhibition causes a rise in these peptides. Previous studies of
neprilysin inhibition in combination with ACE inhibitors have shown an excess of
angio-oedema and no convincing evidence of a survival beneﬁt: equally, the
evidence in favour of using ARAs instead of ACE inhibitors has been equivocal.
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In PARADIGM-HF, 8442 patients with NYHA class II–IV
symptoms were randomized to either LCZ696 (200mg
twice daily) or enalapril (10mg twice daily), as well as
other standard therapy. The average age of the patients
was 64 years, 22% were women and 5% were black. The
average left ventricular ejection fraction was just under
30%, and the cause of heart failure was ischaemic
heart disease in 60%. Over 90% of patients were on
a beta-blocker, and over half were on a mineralocorticoid
receptor antagonist.
The trial was stopped early for overwhelming beneﬁt in
March, 2014 (Figure 1). The primary outcome (the com-
posite of death from cardiovascular causes or hospitaliza-
tion for heart failure) was reduced, with a hazard ratio of
0.8 for LCZ696 against enalapril. Both components of the
end point were reduced, with, in addition, a reduction in
all-cause mortality of 16%. LCZ696 also reduced the
symptoms of heart failure more than enalapril.
There is no doubting the strength and robustness of the
study design and conduct. LCZ696 is unequivocally supe-
rior to enalapril at the doses used. Some might argue that
the dose of enalapril should have been 20mg twice daily:
this was the ﬁnal dose target in the Cooperative North Scan-
dinavian Enalapril Survival Study (CONSENSUS),2 but
10mg twice daily has been shown to improve mortality in
Studies of Left Ventricular Dysfunction,3 and the average
dose of enalapril achieved in the CONSENSUS study was,
in fact, just under 10mg twice daily.2 It seems surprising
that an agent that will increase the level of natriuretic
peptide is helpful given that natriuretic peptide levels are
already high in patients with heart failure. It may be,
however, that the beneﬁcial effect of LCZ696 is mediated
through an increase in other hormones
The results of PARADIGM-HF are likely to have a major
impact on the future management of chronic heart failure.
Whether it means that we should be offering wholesale
change in therapy to all our patients with heart failure
and reduced left ventricular ejection fraction is not yet
clear and may depend, at least in part, on the price of
the new drug once it has a name!
Confirm HF
Presented by Piotr Ponikowski, Wrocław Medical University,
Poland
Patients with chronic heart failure are very commonly
anaemic and, in turn, that anaemia is often because of
iron deﬁciency.4 Further, many patients—perhaps as
many as 40%—have iron deﬁciency, even in the absence
of overt anaemia.5 Iron replacement therapy is an obvious
potential treatment, and a previous study, FAIR-HF, sug-
gested that intravenous iron carboxymaltose could
improve patients’ symptoms and exercise capacity.6
The aim of CONFIRM-HF was to assess the beneﬁts of
long-term iron replacement therapy with intravenous iron
carboxymaltose.7 Patients with iron deﬁciency (304), de-
ﬁned as serum ferritin level below 100ng/mL, or between
100 and 300ng/mL if transferrin saturation (TSAT)
<20%, were eligible if their haemoglobin was less than
15g/dL. Patients were randomized to receive iron
carboxymaltose that was given using a schedule to achieve
iron repletion followed by maintenance iron therapy if re-
quired for 1 year (where the last iron dosing could be at
Figure 1 The primary end point (cardiovascular death or ﬁrst
hospitalization for heart failure) in PARADIGM-HF (taken from
reference 1).
Figure 2 The secondary end point of time to ﬁrst hospitalization
as a result of worsening heart failure in CONFIRM-HF (taken
from reference 7).
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36weeks). The primary end point was change in 6-min
walk test (6MWT) distance from baseline to Week 24.
The average age of the patients was 69, and just under
half were women. Average left ventricular ejection fraction
was 37% with slightly more in NYHA class II than III.
NT-proBNP was markedly raised at over 2000 pg/mL.
Average haemoglobin was 12.4 g/dL; TSAT was 19%
and ferritin was 57 ng/mL.
There was a signiﬁcant increase in 6MWTwith the differ-
ence between placebo and iron being 33m (P<0.002). The
difference continued out to 1-year follow-up. There were
signiﬁcant improvements in fatigue score and quality of life
(using the Kansas City Cardiomyopathy Questionnaire)
with iron relative to placebo and a marked reduction in
the composite of death or ﬁrst hospitalization for worsening
heart failure (Figure 2).
There are still many questions about iron replacement
therapy. How to measure iron deﬁciency remains a prob-
lem: ferritin as an acute-phase reactant is an unreliable
indicator, and directly measuring iron and TSAT is likely
to be more robust. Whether different intravenous iron
preparations differ in their biological effect is not clear—
but ferric carboxymaltose certainly has the advantage that
it can be very readily used with very low risk. Whether
oral iron would have the same effect is not known. How-
ever, oral iron is often poorly tolerated and compliance
is poor: intravenous repletion is reliable and robust.
A ﬁnal worry is how far a given patient with iron deﬁ-
ciency should be investigated. Patients with heart failure
are a population in whom bowel cancers are common:
should they all have upper and lower gastrointestinal
endoscopies if found to be iron deﬁcient?
Signify
Presented by K Fox, Imperial College, Royal Brompton Hospital,
London, UK
In patients with angina, heart rate slowing with
ivabradine, the If inhibitor, results in a reduction in angina.
The SHIFT trial added considerably to the weight of data
suggesting that heart rate lowering was a good therapeutic
target in patients with chronic heart failure who were in si-
nus rhythm. In SHIFT, ivabradine reduced the risk of cardio-
vascular death or hospital admission for worsening heart
failure in patients with a resting heart rate of 70 per minute
or higher. Ivabradine is increasingly being used for patients
with heart failure and a resting heart rate over 70, and there
was thus some concern in heart failure circles when the
SIGNIFY trial was stopped earlier this year because of a
signal that there might be harm associated with its use.
SIGNIFY was a trial involving 19102 patients with
stable coronary artery disease but no clinical heart failure
and a heart rate of 70 beats per minute or more.8
Patients with angina limiting their activity (12,049)
were included. Patients were randomized to receive
ivabradine or placebo, titrated if needed to a dose of
10mg twice a day to achieve a resting heart rate of
55–60. The composite primary end point was cardiovas-
cular death or non-fatal myocardial infarction.
The mean age of the patients was 65, and 72.4% were
men. The average resting heart rate was 77.2 beats per
minute. Mean left ventricular ejection fraction was 56%.
Patients (83%) were taking a beta-blocker, and just under
5% were taking a rate-limiting calcium antagonist.
Ivabradine reduced the resting heart rate at 3months by
10 beats per minute compared with placebo.
The trial was stopped early because of a small (but signiﬁ-
cant) increase in the primary end point in thosewith symptom-
atic angina (Canadian Cardiovascular Society class II–IV).
However, the overall result in the total study population
was neutral (hazard ratio for ivabradine, 1.08; P=0.20)
with, unsurprisingly, an increase risk of bradycardia with
ivabradine (18.0 vs. 2.3% in the placebo group, P<0.001).
It is a surprising ﬁnding. There is a huge body of epide-
miological research showing that the risk of ischaemic
cardiac events increases with increasing resting heart rate
and evidence that reducing heart rate reduces that risk,
particularly in patients with impaired left ventricular
function. It may simply be that heart rate lowering is
helpful in relieving angina symptoms, but that in patients
with normal ventricular function, reducing heart rate is
not beneﬁcial in terms of prognosis. Another intriguing
question was raised by Roberto Ferrari (University Hospital
of Ferrara, Italy). The subgroup of patients who were also
taking a rate-limiting calcium antagonist or strong inhibitor
of the cytochrome P450, CYP3A4, had a higher risk of non-
fatal myocardial infarction, suggesting that the risk may be
associated with excessive heart rate lowering.
As far as managing patients with heart failure is con-
cerned, however, the presentations at the ESC were
reassuring: there is no suggestion of an increase in risk
associated with ivabradine in patients with impaired left
ventricular systolic dysfunction, and it can continue to
be used with conﬁdence in this population.
Atrial ﬁbrillation, beta-blockers, and
heart failure
Presented by Dipak Kotecha (University of Birmingham, UK)
Resting heart rate has become an important target in
treating patients with heart failure in sinus rhythm, but
it is less clear whether heart rate control has anything
to offer patients with heart failure in atrial ﬁbrillation9—
who, after all, constitute around a quarter to a third of
the population of patients with heart failure.
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Dr Kotecha presented the results of an individual patient
meta-analysis from 10 trials of beta-blockers in patients
with heart failure as a result of left ventricular systolic
dysfunction: trials had to include patients with a reduced
ejection fraction, have at least 300 patients, include all-
cause death as an end point, and have at least 6months’
follow-up. Of 18254 patients, 3066 patients (17% of the
total) had atrial ﬁbrillation at baseline.10 The outcome
wasworse for patients in atrial ﬁbrillation (21%died during
1.5 years’ follow-up vs. 16% of those in sinus rhythm), but
whilst beta-blockers were highly efﬁcacious in reducing
the risk of death for patients in sinus rhythm, they were
not associated with any improvement in prognosis for
patients with atrial ﬁbrillation. The lack of beneﬁt from
beta-blockers was consistent across all subgroups of
patients with atrial ﬁbrillation studied, including age, sex,
left ventricular ejection fraction, NYHA class, heart rate,
and baseline medical therapy
It is always difﬁcult to extract data on subgroups from
large trials to highlight groups that might not beneﬁt.
Nevertheless, the data are important and ﬁt with other
work suggesting that patients with atrial ﬁbrillation
behave differently to those in sinus rhythm. However,
the ﬁndings do not translate into a ‘ban’ on beta-blockers
for those in atrial ﬁbrillation: rate control is often vital
for symptom relief, and beta-blockers certainly appear
safe in this meta-analysis. There is now a need for a
randomized controlled outcome study of beta-blockers
in patients with heart failure and atrial ﬁbrillation.
Vagal stimulation in heart failure
There were two studies presented on vagal stimulation in
patients with chronic heart failure. Chronic heart failure
is associated with abnormal sympatho-vagal balance with
increased sympathetic, and decreased parasympathetic,
nervous system activity. Decreasing the sympathetic
activity with beta-blockers is unequivocally helpful, but
less is known about the effect of increasing parasympa-
thetic activity. One possible approach is direct stimula-
tion of the vagus nerve(s), the dominant source of
parasympathetic innervation of the heart. A device simi-
lar in appearance to a standard pacemaker is implanted
in a pre-pectoral pocket connected to a standard pacing
lead positioned in the apex of the right ventricle. It is also
connected to a stimulator cuff implanted around the
vagus nerve in the neck.
(1) Inder Anand (University of Minnesota Medical School,
USA) presented the results of the Autonomic Neural
Regulation Therapy to Enhance Myocardial Function
in Heart Failure, sponsored by Cyberonics.11 Sixty
patients in India received a device to stimulate either
the right (n=29) or left (n=31) vagus. Patients had
NYHA class II or III symptoms and an average left ven-
tricular ejection fraction of 32%. At 6months, there
was a 4.5% increase in LVEF and 4.1-mL decrease in
LV end-systolic volume. There were no differences be-
tween left-sided and right-sided systems. There were
increases in 6-min walk distance and improvements
in quality of life.
A key problem in interpreting the results is the absence
of a control group. The medical literature is bedevilled
with modest-sized studies of interesting interventions,
particularly of devices, that appear to show beneﬁts, often
in somewhat subjective end points, such as quality of life.
(2) Faiez Zannad (Université de Lorraine, Nancy, France)
presented the results of Neural Cardiac Therapy for
Heart Failure, sponsored by Boston Scientiﬁc.12
Ninety-six patients were randomized 2:1 to receive
the device, with the control subjects having the im-
plantation but receiving no therapy. The sham proce-
dure is vital to make sure that placebo effects are not
interpreted as being signals of beneﬁt. Patients had
class II–III symptoms, had impaired left ventricular
systolic function, and were in sinus rhythm.
There was no effect of the vagal stimulator on left
ventricular end-systolic dimension, the primary end point
of the study, or any other index of left ventricular re-
modelling. There was no effect on functional capacity
assed by peak oxygen consumption. There were improve-
ments in quality of life and NYHA class, but these might
be related to un-blinding: at least some patients could tell
if they were receiving active treatment from the sensation
in their necks.
At the moment, it is difﬁcult to know what to make of
vagal stimulation. It is a concern that the sham-controlled
study demonstrated no signiﬁcant effects, a problem with
trials of devices previously where there can be a large pla-
cebo effect from device implantation alone. The Increase
of Vagal Tone in Chronic Heart Failure trial13 aims to re-
cruit up to 650 patients to a study comparing right-sided
vagal stimulation to optimal medical therapy. Although
it will have the problem of the lack of a sham-operated
control group, the primary end point of all-cause mortal-
ity and heart failure hospitalization is likely to be free of
a large placebo effect.
Declaration of interest
Professor Clark andDr. Pellicori have no conﬂicts to declare.
Clinical trials update from the ESC meeting 2014 85
© 2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. ESC Heart Failure 2014; 1: 82–86
DOI: 10.1002/ehf2
References
1. McMurray JJ1, Packer M, Desai AS,
Gong J, Lefkowitz MP, Rizkala AR,
Rouleau JL, Shi VC, Solomon SD,
Swedberg K, Zile MR. The PARADIGM-
HF Investigators and Committees.
Angiotensin-neprilysin inhibition versus
enalapril in heart failure. N Engl J Med
2014;371:993–1004.
2. The CONSENSUS Trial Study Group.
Effects of enalapril on mortality in severe
congestive heart failure: results of the
Cooperative North Scandinavian Enala-
pril Survival Study (CONSENSUS). N
Engl J Med 1987;316:1429–1435.
3. The SOLVD Investigators. Effect of enal-
april on survival in patients with re-
duced left ventricular ejection fractions
and congestive heart failure. N Engl J
Med 1991;325:293–302.
4. Witte KK, Desilva R, Chattopadhyay S,
Ghosh J, Cleland JG, Clark AL. Are
hematinic deﬁciencies the cause of ane-
mia in chronic heart failure? Am Heart J
2004;147:924–930.
5. Okonko DO, Mandal AKJ, Missouris CG,
Poole-Wilson PA. Disordered iron homeo-
stasis in chronic heart failure: prevalence,
predictors, and relations to anemia, exer-
cise capacity, and survival. J Am Coll
Cardiol 2011;58:1241–1251.
6. Anker SD1, Comin Colet J, Filippatos G,
Willenheimer R, Dickstein K, Drexler H,
Lüscher TF, Bart B, BanasiakW,Niegowska
J, Kirwan BA, Mori C, von Eisenhart
Rothe B, Pocock SJ, Poole-Wilson PA,
Ponikowski P; FAIR-HF Trial Investiga-
tors. Ferric carboxymaltose in patients
with heart failure and iron deﬁciency. N
Engl J Med 2009;361:2436–2448.
7. Ponikowski P, van Veldhuisen DJ,
Comin-Colet J, Ertl G, Komajda M,
Mareev V, McDonagh T, Parkhomenko
A, Tavazzi L, Levesque V, Mori C,
Roubert B, Filippatos G, Ruschitzka F,
Anker SD; for the CONFIRM-HF Investi-
gators. Beneﬁcial effects of long-term
intravenous iron therapy with ferric
carboxymaltose in patients with symp-
tomatic heart failure and iron deﬁciency.
Eur Heart J 2014; doi:10.1093/eurheartj/
ehu385, in press.
8. Fox K, Ford I, Steg PG, Tardif JC,
Tendera M, Ferrari R; the SIGNIFY
Investigators. Ivabradine in stable
coronary artery disease without clinical
heart failure. N Engl J Med 2014;
doi:10.156/NEJMoa1406430.
9. Cullington D, Goode KM, Zhang J,
Cleland JG, Clark AL. Is heart rate im-
portant for patients with heart failure
in atrial ﬁbrillation? JACC Heart Fail
2014;2:213–220.
10. Kotecha D, Holmes J, Krum H, Altman
DG, Manzano L, Cleland JG, Lip GY,
Coats AJ, Andersson B, Kirchhof P, von
Lueder TG, Wedel H, Rosano G, Shibata
MC, Rigby A, Flather MD; on behalf of
the Beta-Blockers in Heart Failure Col-
laborative Group. Efﬁcacy of β blockers
in patients with heart failure plus atrial
ﬁbrillation: an individual-patient data
meta-analysis. Lancet pii: S0140-6736(14)
61373-8. doi:10.1016/S0140-6736(14)
61373-8. Epub ahead of print 2 Sept
2014.
11. Premchand RK, Sharma K, Mittal S,
Monteiro R, Dixit S, Libbus I, DiCarlo
LA, Ardell JL, Rector TS, Amurthur B,
KenKnight BH, Anand IS. Autonomic
regulation therapy via left or right cervi-
cal vagus nerve stimulation in patients
with chronic heart failure: results of
the ANTHEM-HF trial. J Card Fail pii:
S1071-9164(14)01189-0. doi:10.1016/j.
cardfail.2014.08.009. Epub ahead of
print 22 Aug 2014.
12. Zannad F, De Ferrari GM, Tuinenburg
AE, Wright D, Brugada J, Butter C, Klein
H, Stolen C, Meyer S, Stein KM,
Ramuzat A, Schubert B, Daum D, Neuzil
P, Botman C, Caste MA, D’Onofrio A,
Solomon SD, Wold N, Ruble SB. Chronic
vagal stimulation for the treatment of
low ejection fraction heart failure:
results of the neural cardiac therapy for
heart failure (NECTAR-HF) randomized
controlled trial. Eur Heart J;doi:10.1093/
eurheartj/ehu345 pii: ehu345. Epub
ahead of print 31 Aug 2014.
13. Hauptman PJ, Schwartz PJ, Gold MR,
Borggrefe M, Van Veldhuisen DJ, Star-
ling RC, Mann DL. Rationale and study
design of the increase of vagal tone in
heart failure study: INOVATE-HF. Am
Heart J 2012;163:954–962.
86 A. L. Clark and P. Pellicori
© 2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. ESC Heart Failure 2014; 1: 82–86
DOI: 10.1002/ehf2
